Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSL001
MIFTS: 61

Measles

Categories: Eye diseases, Infectious diseases, Mental diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Measles

About this section

MalaCards integrated aliases for Measles:

Name: Measles 12 73 20 29 54 42 3 44 15 17 70 32
Morbilli 12
Rubeola 20

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Skin diseases Eye diseases Smell/Taste diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8622
ICD9CM 34 055
MeSH 44 D008457
NCIt 50 C96406
SNOMED-CT 67 154338006
UMLS 70 C0025007
Sources

Summaries for Measles

About this section
MedlinePlus : 42 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as morbilli, is related to subacute sclerosing panencephalitis and rubella, and has symptoms including fever, cough and conjunctivitis. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Sodium citrate and Citric acid have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles is a highly contagious virus that can lead to complications.

Wikipedia : 73 Measles is a highly contagious infectious disease caused by measles virus. Symptoms usually develop... more...

Sources

Related Diseases for Measles

About this section

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 861)
# Related Disease Score Top Affiliating Genes
1 subacute sclerosing panencephalitis 32.5 TNF TLR3 SLAMF1 IL6 IL2 IFNA1
2 rubella 32.3 TNF TLR3 IL6 IL2 IFNB1 IFNAR2
3 mumps 31.8 TNF TLR3 STAT1 IL6 IL2 IFNB1
4 exanthem 31.7 TNF IL6 IL2 IFNA1 IFIH1
5 poliomyelitis 31.5 TNF TLR3 IFNA1 IFIH1 DDX58
6 encephalitis 31.5 TNF TLR3 TLR2 IL6 IFNB1 DDX58
7 chickenpox 31.4 TNF STAT1 IL6 IL2 IFNB1 IFNA1
8 conjunctivitis 31.3 TNF TLR3 IL6 IL2
9 pneumonia 31.2 TNF TLR3 TLR2 IL6
10 tetanus 31.1 TNF IL6 IL2 HLA-A
11 myelitis 31.1 TNF IL6 IFNB1
12 yellow fever 31.0 STAT1 IL6 IFNB1 DDX58
13 haemophilus influenzae 31.0 TNF TLR2
14 appendicitis 30.9 TNF IL6 IL2
15 disease by infectious agent 30.9 TNF TLR2 IL6 IL2 IFNB1 IFNA1
16 crohn's disease 30.9 TNF TLR2 IL6 IL2
17 meningitis 30.8 TNF TLR2 IL6 IL2 CD46
18 hepatitis a 30.8 TNF TLR3 IFNA1
19 vaccinia 30.8 TNF STAT1 IL6 IL2 IFNB1 IFNA1
20 allergic disease 30.8 TNF TLR2 IL6 IL2
21 otitis media 30.7 TNF TLR2 IL6
22 enterocolitis 30.7 TNF IL6 CD46
23 diarrhea 30.6 TNF STAT1 IL6 IL2 IFNB1 IFNA1
24 hepatitis 30.6 TNF IFNAR2 IFNA1 IFIH1 EIF2AK2 DDX58
25 bacterial infectious disease 30.6 TNF TLR3 TLR2 IL6 IFNB1
26 bronchitis 30.6 TNF TLR2 STAT1 IL6
27 rabies 30.6 TLR3 STAT1 IFNA1 DDX58
28 herpes simplex 30.6 TLR3 TLR2 STAT1 IFNB1 IFNA1 IFIH1
29 dengue virus 30.6 TNF IFIH1 DDX58 CD209
30 optic neuritis 30.6 TNF IL6 HLA-A
31 newcastle disease 30.6 TNF TLR3 IFNB1 IFNA1 EIF2AK2 DDX58
32 stomatitis 30.6 TNF IL6 IL2 IFNB1 IFNA1 EIF2AK2
33 inflammatory bowel disease 30.5 TNF TLR3 TLR2 STAT1 IL6 IL2
34 west nile virus 30.5 IFNA1 IFIH1 DDX58 CD209
35 parainfluenza virus type 3 30.5 IFNB1 IFNA1 DDX58
36 chikungunya 30.5 TNF STAT1 IL6 DDX58 CD209
37 bronchiolitis 30.5 TNF TLR3 TLR2 IL6 IFNA1
38 myocarditis 30.5 TNF TLR3 IL6 IL2 IFNA1
39 gastroenteritis 30.5 TNF IL6 IFNA1
40 dengue disease 30.5 TNF IFNB1 IFNA1 CD209
41 acquired immunodeficiency syndrome 30.4 TNF IL6 IL2 IFNA1
42 bacterial pneumonia 30.4 TNF TLR2 IL6
43 viral encephalitis 30.4 TNF TLR3 IL6 IFNB1 IFNA1
44 dermatitis 30.4 TNF TLR2 STAT1 IL6 IL2
45 erythema multiforme 30.4 TNF IL6 IL2
46 hepatitis b 30.4 TNF TLR3 TLR2 STAT1 IL6 IFNB1
47 viral pneumonia 30.4 TNF TLR3 IL6 IFNB1 DDX58
48 kawasaki disease 30.4 TNF IL6 FCGR2B
49 syphilis 30.4 TNF IL6 CD209
50 otosclerosis 30.4 IL6 HLA-A CD46

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles
Sources

Symptoms & Phenotypes for Measles

About this section

Symptoms:

12
  • • fever
  • • cough
  • • conjunctivitis
  • • coryza
  • • maculopapular

UMLS symptoms related to Measles:


fever; pruritus; exanthema; koplik spots

MGI Mouse Phenotypes related to Measles:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 ADAR CD209 DDX58 EIF2AK2 FCGR2B HLA-A
2 immune system MP:0005387 10.22 ADAR DDX58 EIF2AK2 FCGR2B HLA-A IFIH1
3 homeostasis/metabolism MP:0005376 10.21 ADAR CD209 DDX58 FCGR2B IFIH1 IFNAR2
4 mortality/aging MP:0010768 10 ADAR DDX58 EIF2AK2 FCGR2B HLA-A IFIH1
5 liver/biliary system MP:0005370 9.91 ADAR DDX58 FCGR2B IFIH1 IL2 IL6
6 neoplasm MP:0002006 9.65 DDX58 EIF2AK2 IFNAR2 IFNB1 IL2 IL6
7 respiratory system MP:0005388 9.23 FCGR2B IL2 IL6 MSN STAT1 TLR2
Sources

Drugs & Therapeutics for Measles

About this section

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
3 Citrate Phase 4
4 Vaccines Phase 4
5 Immunologic Factors Phase 4
6 Liver Extracts Phase 4
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
8
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
9
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
10
Lactitol Approved, Investigational Phase 3 585-86-4 157355
11 Orange Approved Phase 3
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
13
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
14
Sulfamethoxazole Approved Phase 3 723-46-6 5329
15
Petrolatum Approved, Investigational Phase 3 8009-03-8
16
Podophyllin Approved Phase 3 9000-55-9
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
19 Fanasil, pyrimethamine drug combination Phase 3
20 Pharmaceutical Solutions Phase 3
21 Immunoglobulins, Intravenous Phase 3
22 Vitamin B9 Phase 3
23 Folic Acid Antagonists Phase 3
24 Antiparasitic Agents Phase 3
25 Antimalarials Phase 3
26 Vitamin B Complex Phase 3
27 Folate Phase 3
28 Antiprotozoal Agents Phase 3
29 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 3
31 Retinol palmitate Phase 3
32 Trace Elements Phase 3
33 Nutrients Phase 3
34 retinol Phase 3
35 Micronutrients Phase 3
36 Vitamins Phase 3
37 Hemagglutinins Phase 3
38 Somatomedin B Phase 3
39 taxane Phase 3
40 insulin Phase 3
41 Insulin, Globin Zinc Phase 3
42 Dermatologic Agents Phase 3
43 Keratolytic Agents Phase 3
44
Altretamine Approved Phase 2 645-05-6 2123
45
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
46
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
49
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine Unknown status NCT01486355 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01668745 Phase 4
4 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01644721 Phase 4
5 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
6 Immunogenicity and Safety of AVAXIMâ„¢ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAXâ„¢ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
7 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Completed NCT03071575 Phase 4
8 Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival Completed NCT00168558 Phase 4
9 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
10 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
11 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
12 Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau Completed NCT00168571 Phase 4
13 Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh Completed NCT01700621 Phase 4
14 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
15 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
16 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
17 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
18 Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children Completed NCT03160820 Phase 4
19 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
20 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
21 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
22 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
23 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
24 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
25 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
26 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
27 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
28 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
29 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
30 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Recruiting NCT01770119 Phase 4
31 Randomized, Double-blind, Controlled Phase â…£ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months. Recruiting NCT04364399 Phase 4
32 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
33 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Recruiting NCT04638985 Phase 4
34 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
35 A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children Active, not recruiting NCT03460002 Phase 4
36 Health Effects of Utilising Curative Health System Contacts to Provide Measles Vaccination - a Randomised Controlled Trial Active, not recruiting NCT04220671 Phase 4
37 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Active, not recruiting NCT03330171 Phase 4
38 Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants Unknown status NCT00152204 Phase 3 Sulfadoxine-pyrimethamine used for IPTi;IPTi
39 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
40 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
41 Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone Completed NCT00249769 Phase 3
42 A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP) Completed NCT01536405 Phase 3
43 Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone Completed NCT00412516 Phase 3
44 An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life Completed NCT00560755 Phase 3
45 Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life Completed NCT01681992 Phase 3
46 An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age Completed NCT00566527 Phase 3
47 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762) Completed NCT01621802 Phase 3
48 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age Completed NCT00984295 Phase 3
49 A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAXâ„¢ and M-M-R IIâ„¢ in Healthy Children Completed NCT00975507 Phase 3
50 Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age Completed NCT00985166 Phase 3

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Sources

Genetic Tests for Measles

About this section

Genetic tests related to Measles:

# Genetic test Affiliating Genes
1 Measles 29
Sources

Anatomical Context for Measles

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

19
Skin

MalaCards organs/tissues related to Measles:

40
Eye, T Cells, Bone, Bone Marrow, Endothelial, Liver, B Cells
Sources

Publications for Measles

About this section

Articles related to Measles:

(show top 50) (show all 23938)
# Title Authors PMID Year
1
Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2. 61 42
33582147 2021
2
A scorecard of progress towards measles elimination in 15 west African countries, 2001-19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data. 61 42
33607028 2021
3
The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya. 42 61
33531015 2021
4
Measles virus-induced immunosuppression in SLAM knock-in mice. 54 61
20200244 2010
5
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. 54 61
20071568 2010
6
Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). 54 61
20042501 2010
7
Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR. 54 61
20087926 2010
8
Restriction analysis of otosclerosis-associated CD46 splicing variants. 54 61
19597833 2010
9
Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. 54 61
19806178 2009
10
Laboratory confirmation of measles in elimination settings: experience from the Republic of the Marshall Islands, 2003. 61 54
19274360 2009
11
Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. 61 54
19007958 2009
12
Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. 54 61
19319188 2009
13
Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis. 54 61
18677279 2008
14
Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. 61 54
18715339 2008
15
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. 61 54
18559536 2008
16
High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation. 61 54
18455798 2008
17
Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. 61 54
18419254 2008
18
Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. 54 61
18325643 2008
19
[Host genetic factors for the development of SSPE]. 54 61
17695285 2007
20
Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. 54 61
17695519 2007
21
Expression of measles virus receptors in otosclerotic, non-otosclerotic and in normal stapes footplates. 54 61
17294206 2007
22
Downregulation of human CD46 by adenovirus serotype 35 vectors. 54 61
17377598 2007
23
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. 54 61
17492596 2007
24
Current problems of measles control in Japan and Western Pacific Region. 61 54
17368662 2007
25
Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. 61 54
17356690 2007
26
A case of common variable immunodeficiency syndrome associated with Takayasu arteritis. 61 54
17304891 2007
27
Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. 61 54
17070884 2007
28
Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. 54 61
17135325 2007
29
Detection of circulating antigen with a MAb-based sandwich-ELISA and its comparison with specific IgM detection in sera of patients with hemorrhagic fever with renal syndrome. 54 61
17316085 2007
30
Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone (GnRH) chimeric peptide. 61 54
17064933 2006
31
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. 54 61
17133484 2006
32
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. 54 61
17062694 2006
33
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. 61 54
16645169 2006
34
Identification of amino acid residues involved in the interaction between measles virus Haemagglutin (MVH) and its human cell receptor (signaling lymphocyte activation molecule, SLAM). 54 61
16889684 2006
35
The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. 61 54
16782388 2006
36
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. 61 54
16728275 2006
37
Assessment of the performance of a definition of a suspected measles case: implications for measles surveillance. 61 54
16723063 2006
38
Immunosuppression caused by measles virus: role of viral proteins. 61 54
16237742 2006
39
Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. 54 61
16223530 2005
40
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. 61 54
15920733 2005
41
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. 61 54
16260741 2005
42
Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain. 54 61
16207972 2005
43
Gene expression profiles in peripheral blood mononuclear cells from patients with subacute sclerosing panencephalitis using oligonucleotide microarrays. 61 54
16036810 2005
44
Localization of regions in CD46 that interact with adenovirus. 54 61
15919905 2005
45
CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. 54 61
15845515 2005
46
Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? 54 61
15659756 2005
47
Rescue and propagation of fully retargeted oncolytic measles viruses. 54 61
15685166 2005
48
Expression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. 61 54
15337611 2004
49
Measles virus receptors: SLAM and CD46. 61 54
15248250 2004
50
Variation in vaccine response in normal populations. 54 61
15165177 2004
Sources

Variations for Measles

About this section
Sources

Expression for Measles

About this section
Search GEO for disease gene expression data for Measles.
Sources

Pathways for Measles

About this section

Pathways related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.96 TNF TLR3 TLR2 STAT1 IL6 IL2
2
Viral mRNA Translation 65
Show member pathways
 13.84 TNF TLR3 TLR2 STAT1 IL6 IL2
3
TGF-Beta Pathway 63
Show member pathways
 13.55 TNF STAT1 IL6 IL2 IFNB1 IFNAR2
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.4 TNF STAT1 IL6 IL2 IFNB1 IFNAR2
5
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.09 TNF TLR3 TLR2 STAT1 IL6 IL2
6
Human cytomegalovirus infection 36
Show member pathways
 12.98 TNF TLR3 TLR2 STAT1 IL6 IFNB1
7
Allograft rejection 36 1
Show member pathways
 12.88 TNF STAT1 IL6 IL2 IFNA1 HLA-A
8
Pathways in cancer 36
12.83 STAT1 IL6 IL2 IFNAR2 IFNA1
9
NF-KappaB Family Pathway 63
Show member pathways
 12.75 TNF TLR3 TLR2 IL6 IL2 EIF2AK2
10
PI3K-Akt signaling pathway 36
Show member pathways
 12.73 TNF TLR3 TLR2 STAT1 IL6 IL2
11
RANK Signaling in Osteoclasts 63
Show member pathways
 12.67 TNF STAT1 IFNB1 IFNAR2 FCGR2B
12
Interferon gamma signaling 65
Show member pathways
 12.63 STAT1 IFNB1 IFNAR2 IFNA1 HLA-A EIF2AK2
13
T cell receptor signaling pathway 36
Show member pathways
 12.62 TNF TLR2 STAT1 IL6 IL2
14
Th17 cell differentiation 36
Show member pathways
 12.62 TNF TLR2 STAT1 IL6 IL2
15
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.62 TLR3 IL6 IFNB1 IFNA1 IFIH1 DDX58
16
Immune response IL-23 signaling pathway 23
Show member pathways
 12.61 TNF STAT1 IL6 IL2 EIF2AK2
17
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.58 TNF IL2 IFNB1 IFNAR2 IFNA1 HLA-A
18
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.57 TNF IFNB1 IFNA1 IFIH1 DDX58
19
NF-kappaB Signaling 4
12.54 TNF TLR3 TLR2 STAT1 IL2 IFNA1
20
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.5 TNF TLR3 TLR2 IL6 IFNB1 IFNA1
21
JAK-STAT signaling pathway 36
Show member pathways
 12.49 STAT1 IL6 IL2 IFNB1 IFNAR2 IFNA1
22
Herpes simplex virus 1 infection 36
12.43 TNF TLR3 TLR2 STAT1 IL6 IFNB1
23
Human T-cell leukemia virus 1 infection 36
12.35 TNF IL6 IL2 HLA-A
24
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.32 TNF TLR3 TLR2 IL6 IFNB1
25
Toll Comparative Pathway 63
Show member pathways
 12.31 TNF TLR3 STAT1 IL6
26
NOD-like receptor signaling pathway 36
12.31 TNF STAT1 IL6 IFNB1 IFNAR2 IFNA1
27
Measles 36
Show member pathways
 12.31 TNF TLR3 TLR2 STAT1 SLAMF1 MSN
28
Necroptosis 36
Show member pathways
 12.3 TNF TLR3 STAT1 IFNB1 IFNAR2 IFNA1
29
C-type lectin receptor signaling pathway 36
Show member pathways
 12.28 TNF STAT1 IL6 IL2 CD209
30
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.27 TNF STAT1 IL6 IL2 IFNB1 IFNAR2
31
Colorectal Cancer Metastasis 63
12.25 TNF TLR3 TLR2 STAT1 IL6
32
Bacterial infections in CF airways 23
Show member pathways
 12.25 TNF TLR2 STAT1 IL6 IFNB1
33
IL-1 Family Signaling Pathways 64
Show member pathways
 12.24 TNF TLR2 STAT1 IL6
34
Phagosome 36
12.16 TLR2 HLA-A FCGR2B CD209
35
Yersinia infection 36
12.11 TNF IL6 IL2 IFNB1
36
Tuberculosis 36
12.11 TNF TLR2 STAT1 IL6 IFNB1 IFNA1
37
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.07 TNF SLAMF1 IL6 IL2 CD209
38
MAPK Pathway 69
Show member pathways
 12.06 TLR3 TLR2 STAT1 IL2
39
Interferon Pathway 63
11.96 STAT1 IL6 IFNB1 IFNAR2 IFNA1
40
Th17 Differentiation Pathway 64
Show member pathways
 11.91 TLR3 TLR2 STAT1 IL6
41
Th1 Differentiation Pathway 64
Show member pathways
 11.87 TNF TLR3 TLR2 STAT1 IL6 IL2
42
Dendritic Cells Developmental Lineage Pathway 64
11.84 TNF SLAMF1 IL6 IL2 IFNB1 CD209
43
Glucocorticoid receptor regulatory network 1
11.8 STAT1 IL6 IL2
44
IgA-Producing B Cells in the Intestine 64
11.78 TNF TLR2 SLAMF1 IL6 FCGR2B
45
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.71 TNF IL2 IFNAR2 HLA-A
46
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 TNF IL6 IL2
47
Legionellosis 36
11.63 TNF TLR2 IL6
48
Photodynamic therapy-induced AP-1 survival signaling. 1
11.58 TNF IL6 IL2
49
Malaria 36
11.57 TNF TLR2 IL6
50
all-trans-Retinoic Acid Mediated Apoptosis 63
11.54 IL6 IFNB1 IFNA1
Sources

GO Terms for Measles

About this section

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF SLAMF1 NECTIN4 IL6 IL2 IFNB1
2 cell surface GO:0009986 9.23 TNF TLR3 TLR2 SLAMF1 MSN HLA-A

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TNF TLR3 TLR2 STAT1 IL6 IL2
2 positive regulation of gene expression GO:0010628 10.14 TNF TLR3 TLR2 MSN IL6 DDX58
3 immune response GO:0006955 10.13 TNF TLR3 TLR2 IL6 IL2 HLA-A
4 adaptive immune response GO:0002250 10.12 SLAMF1 IL2 IFNB1 IFNA1 HLA-A CD46
5 inflammatory response GO:0006954 10.08 TNF TLR3 TLR2 IL6 FCGR2B
6 cytokine-mediated signaling pathway GO:0019221 10.05 TNF STAT1 IL6 IL2 IFNB1 IFNAR2
7 innate immune response GO:0045087 10.02 TLR3 TLR2 SLAMF1 IFIH1 HLA-A EIF2AK2
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF TLR3 TLR2 IL6 EIF2AK2
9 immune system process GO:0002376 10 TLR3 TLR2 SLAMF1 IL2 IFIH1 HLA-A
10 defense response GO:0006952 9.97 TNF TLR3 STAT1 IFNB1 IFNA1 FCGR2B
11 defense response to Gram-positive bacterium GO:0050830 9.96 TNF TLR2 IL6 HLA-A
12 positive regulation of inflammatory response GO:0050729 9.95 TNF TLR3 TLR2 IL2
13 viral entry into host cell GO:0046718 9.94 SLAMF1 NECTIN4 CD46 CD209
14 positive regulation of JNK cascade GO:0046330 9.93 TNF TLR3 SLAMF1 FCGR2B
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.93 TNF TLR3 TLR2 EIF2AK2
16 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR3 TLR2 IL6 IFIH1 DDX58
17 positive regulation of interferon-gamma production GO:0032729 9.92 TNF TLR3 IL2 HLA-A
18 positive regulation of T cell proliferation GO:0042102 9.92 IL6 IL2 CD46 CD209
19 humoral immune response GO:0006959 9.91 TNF IL6 IFNB1 IFNA1
20 viral process GO:0016032 9.9 STAT1 SLAMF1 NECTIN4 MSN IFIH1 HLA-A
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 TNF IL6 IL2
22 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR3 TLR2 IL6 IFIH1 DDX58
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF STAT1 IL6
24 positive regulation of interferon-beta production GO:0032728 9.87 TLR3 TLR2 IFIH1 DDX58
25 positive regulation of cytokine production GO:0001819 9.86 TNF TLR3 EIF2AK2
26 response to exogenous dsRNA GO:0043330 9.86 TLR3 IFNB1 IFNA1 DDX58
27 negative regulation of viral genome replication GO:0045071 9.85 TNF IFNB1 EIF2AK2
28 positive regulation of interleukin-10 production GO:0032733 9.85 TLR2 IL6 CD46
29 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR3 TLR2 IL6 DDX58
30 type I interferon signaling pathway GO:0060337 9.85 STAT1 IFNB1 IFNAR2 IFNA1 HLA-A ADAR
31 microglial cell activation GO:0001774 9.84 TNF TLR3 TLR2
32 positive regulation of interferon-alpha production GO:0032727 9.83 TLR3 STAT1 IFIH1 DDX58
33 positive regulation of chemokine production GO:0032722 9.83 TNF TLR3 TLR2 IL6 EIF2AK2
34 cellular response to interferon-beta GO:0035458 9.81 TLR3 STAT1 IFNB1
35 cellular response to exogenous dsRNA GO:0071360 9.78 TLR3 IFNB1 IFIH1 DDX58
36 response to interferon-alpha GO:0035455 9.77 IFNAR2 EIF2AK2 ADAR
37 detection of virus GO:0009597 9.72 TLR3 IFIH1 DDX58
38 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6
39 I-kappaB phosphorylation GO:0007252 9.71 TLR3 TLR2
40 positive regulation of podosome assembly GO:0071803 9.71 TNF MSN
41 response to interferon-beta GO:0035456 9.7 STAT1 IFNAR2
42 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
43 necroptotic signaling pathway GO:0097527 9.7 TNF TLR3
44 positive regulation of response to cytokine stimulus GO:0060760 9.69 IFIH1 DDX58
45 vascular endothelial growth factor production GO:0010573 9.69 TNF IL6
46 positive regulation of toll-like receptor signaling pathway GO:0034123 9.68 TLR3 TLR2
47 interleukin-10 production GO:0032613 9.67 TLR2 CD46
48 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.66 IFIH1 DDX58
49 regulation of type III interferon production GO:0034344 9.65 IFIH1 DDX58
50 response to virus GO:0009615 9.56 TNF TLR3 IFNB1 IFNAR2 IFIH1 EIF2AK2

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TNF TLR3 TLR2 STAT1 SLAMF1 NECTIN4
2 identical protein binding GO:0042802 9.91 TNF TLR3 TLR2 STAT1 SLAMF1 NECTIN4
3 transmembrane signaling receptor activity GO:0004888 9.71 TLR3 TLR2 SLAMF1 FCGR2B
4 signaling receptor activity GO:0038023 9.67 TLR3 TLR2 SLAMF1 CD46
5 cytokine activity GO:0005125 9.55 TNF IL6 IL2 IFNB1 IFNA1
6 virus receptor activity GO:0001618 9.26 SLAMF1 NECTIN4 CD46 CD209
7 double-stranded RNA binding GO:0003725 9.1 TLR3 MSN IFIH1 EIF2AK2 DDX58 ADAR
Sources

Sources for Measles

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....